Navigation Links
Unigene Laboratories Granted US Patent for Peptide-Based Technology for Treatment of Obesity
Date:1/11/2012

pany's growth potential and shareholder value; the Company will present full data of oral parathyroid hormone (PTH) analog Phase 2 results in peer review journal and/or prestigious scientific congress; the Company will be successful in seeking a licensing partner for oral PTH program; the Company will continue to build a robust portfolio of feasibility studies on behalf of various pharmaceutical companies evaluating Unigene's Peptelligence™ platform for oral delivery of proprietary peptides across a broad spectrum of high potential valuation therapeutic areas; whether the Company will be able to convert at least one Peptelligence™ feasibility study into a definitive license agreement with significant milestones and royalties; the Company will file an IND and begin Phase 1 clinical testing of its lead metabolic peptide, UGP281, targeting patients with morbid obesity; the Company will select a lead molecule for Type 2 diabetes indication under the joint development vehicle (JDV) with Nordic Bioscience; the Company will announce preclinical results for Type 2 diabetes indication under JDV with Nordic Bioscience; the Company will advance its own pipeline of novel, proprietary peptide product candidates focused on metabolic disease and inflammation; a licensing partner for the Company's oral PTH program will be found and an agreement will be entered into; will present the full date from the Phase 2 PTH study in a peer review journal and/or prestigious scientific congress over the course of 2012; Tarsa's oral calcitonin program will be successful, a product will be approved and any sales-related milestone payments and royalties will be paid to the Company on worldwide sales, excluding China; Tarsa will report top-line results from its TAR01-201 study in the second half of 2012; Tarsa will file an NDA submission to the FDA for OSTORA in the second half of 2012; the Company will file an Investigational New Drug (IND) application with the FDA and initiate Phase 1
'/>"/>
SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Unigene Provides 2012 Business Outlook
2. Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9
3. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
4. Unigene Strengthens Board with the Appointment of Walgreens Executive, Thomas J. Sabatino, Jr.
5. Unigene Reports Third Quarter 2011 Financial Results
6. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
7. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
8. Bedford Laboratories™ Issues Guidance on 2011 Voluntary Recall of Polymyxin B for Injection USP and Vecuronium Bromide for Injection Related to Glass Particulates
9. Quest Diagnostics Completes Acquisition of S.E.D. Medical Laboratories
10. IDEXX Laboratories to Present at J.P. Morgan Healthcare Conference
11. Abaxis Veterinary Reference Laboratories Now Offering Quantitative Lyme Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)...  Eli Lilly and Company (NYSE: ... study in genetically engineered mice examining combination therapy ... N3pG and beta-secretase inhibitor BACE (LY2811376). Data results ... removing clumps of amyloid-beta protein in the brain ... to Alzheimer,s disease (AD) – than use of ...
(Date:7/11/2014)... N.C. , July 11, 2014 ... approaches are evolving across industry sectors to better ... examining better ways to engage with and understand ... inform themselves and make critical purchasing decisions. ... firm, Best Practices, LLC, one area where organizations ...
(Date:7/11/2014)... According to a new ... Material, Application (Healthcare, Homeland security, Industrial application, Nuclear ... Hand-Held Instruments, Fixed, and Installed Instruments) & Geography ... by MarketsandMarkets, the Scintillator Market is expected to ... to 2020, and reach $479.16 Million in 2020. ...
Breaking Medicine Technology:New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Technologies Transforming Consumer Marketing Research Playbook 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4
... World Drug Safety Congress in Boston, MA, ePharmaSolutions announced ... system to support the most recent national and local ... advanced distribution and tracking capabilities. The distribution ... and time consuming process for global biopharmaceutical companies who ...
... The Female Health Company (NASDAQ-CM: FHCO), today announced that its ... $0.05 per share.  The dividend is payable May 10, 2011 ... In January, 2010, the Company announced the initiation of ... dividends since the program,s inception. "The Company,s Board ...
Cached Medicine Technology:ePharmaSolutions Launches Major Release of Its Global Safety Letter Distribution and Tracking Application in More Than 90 Countries 2The Female Health Company Declares 2nd Quarter Dividend of $0.05/share 2The Female Health Company Declares 2nd Quarter Dividend of $0.05/share 3
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most ... outfits, has released its new range of elegant ... are available at discounted prices. Worldwide clients can enjoy ... In the company’s online shop, there are plenty of ... made with great materials. MyDressCity.com’s hot items are prom ...
(Date:7/13/2014)... Epidemiologists forecast an increase in the diagnosed incident ... incident cases in 2013 to 11,568 diagnosed incident cases ... 4.35%, during the forecast period. In 2023, the US ... of aGVHD in the 6MM, with 4,989 diagnosed incident ... diagnosed incident cases of aGVHD, with 704 diagnosed incident ...
(Date:7/13/2014)... A decreased ability to identify odors might indicate ... while examinations of the eye could indicate the ... in the brain, according to the results of ... Association International Conference 2014 (AAIC 2014) in Copenhagen. ... ability to identify odors was significantly associated with ...
(Date:7/13/2014)... Columbus, OH (PRWEB) July 13, 2014 ... Lipitor bellwether trial has been scheduled in July of ... The Lipitor lawsuits are in the discovery process ... Judge Richard M. Gergel is presiding over the multidistrict ... were filed on behalf of individuals who allege that ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Celebrity fitness ... has formed a promotional partnership with Aqua Health Labs ... Omega-3 EPA supplement . The collaboration was recently ... celebrity fitness trainer , actor, model, and a ... trainer for A-List celebrities, he has prepared stars including ...
Breaking Medicine News(10 mins):Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2
... OAKLAND, Calif., Feb. 7 Nytera Tilmon works,at ... for her seven children,all of whom live with asthma. ... new television show revealing Nytera,s story and others,behind the ... "Union Time" and it,s the only national labor-produced TV ...
... Mass., USA (February 7, 2008) After just seven months ... been named the 2007 Best New Journal - Science, Technology ... of the Association of American Publishers (AAP). , This honor, ... for Excellence, comes less than a year after Cell Stem ...
... Transcept Pharmaceuticals,Inc. today announced that Glenn A. ... the 10th Annual BIO CEO & Investor Conference ... Tuesday, February 12, 2008 at,10:15 AM Eastern Time., ... is a specialty pharmaceutical company,deriving significant new patient ...
... March Meeting of American Physical Society will take place March ... scientists are expected to be on hand. The principal ... materials, chemical and biological physics, fluids, polymers, and computation. , ... is both a great showcase for fundamental physics research and ...
... Owners and employees agree that the rising ... WASHINGTON, Feb. 7 Post-primary polling,shows small-business ... voting,segment equal to, and larger than, well-established ... The National Federation of Independent Business (NFIB), ...
... by the body can make the difference between your average ... the United States last year, reveals a new study in ... of Cell Press. , If this natural anti-cancer agent, ... might serve as a targeted chemotherapy for metastatic melanoma, a ...
Cached Medicine News:Health News:Cell Stem Cell named 'Best New Journal' of 2007 2Health News:Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference 2Health News:Physics breakthroughs on tap at New Orleans conference 2Health News:Small Business Turns Out on Super Tuesday 2Health News:Small Business Turns Out on Super Tuesday 3Health News:Natural secretion marks difference between mole and melanoma 2Health News:Natural secretion marks difference between mole and melanoma 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: